Current management of chronic wounds involves regular wound cleaning, antiseptic dressings and, when indicated, antimicrobials. Micropore particle technology (MPPT) is a novel concept for wound healing, aiming to bolster the action of the immune system by disrupting the wound biofilm and restoring the microbiome. Amicapsil is the first MPPT product licensed for clinical use. Patients with a spinal cord injury (SCI) are more likely to develop chronic wounds due to downregulation in their immune response increasing the risk of a minor wound, such as pressure sore, developing into large, non-healing wounds. At the Defence Medical Rehabilitation Centre (DMRC) Stanford Hall, patients with SCI often have chronic wounds causing pain, becoming infected and preventing full engagement with effective rehabilitation. We report on the first case of treatment with Amicapsil at the DMRC Stanford Hall and review MPPT as a potential new paradigm for the treatment of wound healing.
- wound management
- biotechnology & bioinformatics
- rehabilitation medicine
Statistics from Altmetric.com
Contributors RP suggested the idea, provided overarching direction and final comments, LH and KF-C wrote initial draft sections, OOS combined, edited and drafted the complete article. All authors reviewed and approved final draft.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.